Blood basophils from cystic fibrosis patients with allergic bronchopulmonary aspergillosis are primed and hyper-responsive to stimulation by aspergillus.

Slides:

Advertisements

Similar presentations

ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS

Advertisements

Alterations in blood leukocytes of G551D-bearing cystic fibrosis patients undergoing treatment with ivacaftor Preston E. Bratcher, Steven M. Rowe, Ginger.

Serum matrix metalloproteinases in adult CF patients: Relation to pulmonary exacerbation Martin Roderfeld, Timo Rath, Richard Schulz, Werner Seeger,

Monocyte chemoattractant chemokines in cystic fibrosis

Reduced levels of active GLP-1 in patients with cystic fibrosis with and without diabetes mellitus Magnus Hillman, Leif Eriksson, Lena Mared, Karin Helgesson,

Neil E. Alexis, Marianne S. Muhlebach, David B. Peden, Terry L. Noah

Use of high-dose ibuprofen in a pediatric cystic fibrosis center

Omalizumab treatment downregulates dendritic cell FcεRI expression

How does heart rate recovery after sub-maximal exercise correlate with maximal exercise testing in children with CF? Sarah P. Cohen, David M. Orenstein

Scott D. Sagel, Marci K. Sontag, Meg M

Long-term treatment with oral N-acetylcysteine: Affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled.

Evaluation of mold exposure in cystic fibrosis patients' dwellings and allergic bronchopulmonary risk Steffi Rocchi, Bénédicte Richaud-Thiriez, Coralie.

Megan R. Nelson, Craig R. Adamski, Audrey Tluczek

Design and powering of cystic fibrosis clinical trials using pulmonary exacerbation as an efficacy endpoint D.R. VanDevanter, A. Yegin, W.J. Morgan,

Regional ventilation in cystic fibrosis measured by electrical impedance tomography Zhanqi Zhao, Rainald Fischer, Inéz Frerichs, Ullrich Müller-Lisse,

Cirrhosis and other liver disease in cystic fibrosis

Katelyn Krivchenia, Don Hayes, Joseph D. Tobias, Dmitry Tumin

The role of basophil activation test in allergic bronchopulmonary aspergillosis and Aspergillus fumigatus sensitization in cystic fibrosis patients Anna.

Increased serum concentration of G-CSF in cystic fibrosis patients with chronic Pseudomonas aeruginosa pneumonia P.Ø. Jensen, C. Moser, A. Kharazmi,

Safety and early treatment effects of the CXCR2 antagonist SB in patients with cystic fibrosis Richard B. Moss, Sunil J. Mistry, Michael W. Konstan,

Fiona K. Dunlevy, S. Lorraine Martin, Francine de Courcey, J

Advanced glycation end products are elevated in cystic fibrosis-related diabetes and correlate with worse lung function William R. Hunt, Beth R. Helfman,

Claire J. Tipping, Rebecca L. Scholes, Narelle S. Cox

Evaluation of salt supplementation in CF infants

Comparison of real time diagnostic chemistries to detect Pseudomonas aeruginosa in respiratory samples from cystic fibrosis patients J.L. Fothergill,

Alan P Knutsen, Clifford Bellone, Henk Kauffman

An evaluation strategy for potential QTc prolongation with chronic azithromycin therapy in cystic fibrosis Patrick John Lenehan, Craig M. Schramm, Melanie.

Cytokines in nasal lavages and plasma and their correlation with clinical parameters in cystic fibrosis Marthe S. Paats, Ingrid M. Bergen, Marleen Bakker,

A.H. Gifford Journal of Cystic Fibrosis

Initial evaluation of the Parent Cystic Fibrosis Questionnaire—Revised (CFQ-R) in infants and young children Adrianne N. Alpern, Lyndia C. Brumback,

Tregony Simoneau, Gregory S. Sawicki, Carly E. Milliren, Henry A

M. Al-Aloul, M. Jackson, G. Bell, M. Ledson, M. Walshaw

Physiologic endpoints for clinical studies for cystic fibrosis

Antonia V. Bennett, Donald L. Patrick, James F. Lymp, Todd C

E. Tschiedel, H. Grasemann, F. Ratjen Journal of Cystic Fibrosis

The basophil surface marker CD203c identifies Aspergillus species sensitization in patients with cystic fibrosis Bojana Mirković, PhD, Gillian M. Lavelle,

Depression and anxiety in adolescents and adults with cystic fibrosis in the UK: A cross- sectional study Alistair J.A. Duff, Janice Abbott, Carolyn Cowperthwaite,

Meconium ileus in cystic fibrosis is not linked to central repetitive region length variation in MUC1, MUC2, and MUC5AC XueLiang Guo, Rhonda G. Pace,

Stenotrophomonas maltophilia in cystic fibrosis: Improved detection by the use of selective agar and evaluation of antimicrobial resistance P. Goncalves-Vidigal,

Saliva cyclic GMP increases during anaesthesia

Nasal polyposis in lung transplant recipients with cystic fibrosis

Elliott C. Dasenbrook, Gregory S. Sawicki Journal of Cystic Fibrosis

Design and powering of cystic fibrosis clinical trials using rate of FEV1 decline as an efficacy endpoint M.W. Konstan, J.S. Wagener, A. Yegin, S.J.

Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis Geraint B. Rogers, Lucas R. Hoffman,

Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United.

Australian epidemic strain pseudomonas (AES-1) declines further in a cohort segregated cystic fibrosis clinic Amanda L. Griffiths, Danielle F. Wurzel,

Alina A. Ionescu, Lisette S. Nixon, Dennis J. Shale

Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005 F.A. Millar, N.J. Simmonds, M.E. Hodson Journal.

Comparison of two tobramycin nebuliser solutions: Pharmacokinetic, efficacy and safety profiles of T100 and TNS Dorota Sands, Ewa Sapiejka, Grzegorz.

A. Sapet, A. C. Normand, M. Oudyi, N. Stremler- Le Bel, R. Piarroux, J

H. White, A.M. Morton, S.P. Conway, D.G. Peckham

J.E. Spahr, R.B. Love, M. Francois, K. Radford, K.C. Meyer

Impact of IVS8-(TG)m(T)n on IRT and sweat chloride levels in newborns identified by California CF newborn screening Steven Keiles, Ruth Koepke, Richard.

Daniel J. Smith, Gregory J. Anderson, Scott C. Bell, David W. Reid

Michael W. Konstan, David J. Pasta, Jeffrey S. Wagener, Donald R

Chronic pain in adults after thoracotomy in childhood or youth

Serum-surfactant SP-D correlates inversely to lung function in cystic fibrosis Hanne Vebert Olesen, Uffe Holmskov, Peter Oluf Schiøtz, Grith Lykke Sørensen

D.F. Waterhouse, A.M. McLaughlin, C.G. Gallagher

CFTR modulators and pregnancy: Our work has only just begun

‘Peeling paint’ dermatitis as a presenting sign of cystic fibrosis

Inducible nitric oxide synthase expression by peritoneal macrophages in endometriosis- associated infertility Barbara H Osborn, M.D., A.F Haney, M.D.,

N Dauletbaev, K Viel, R Buhl, T.O.F Wagner, J Bargon

Lutz Goldbeck, Sven Zerrer, Tim G. Schmitz Journal of Cystic Fibrosis

David Adeboyeku, Sandra Scott, Margaret E. Hodson

Clinical safety of Food Allergy Herbal Formula-2 (FAHF-2) and inhibitory effect on basophils from patients with food allergy: Extended phase I study

Changing thresholds and incidence of antibiotic treatment of cystic fibrosis pulmonary exacerbations, 1995–2005 Donald R. VanDevanter, Eric P. Elkin,

Absence of a gender gap in survival

Cystic fibrosis and pregnancy in the modern era: A case control study

R. D. Gray, M. Imrie, A. C. Boyd, D. Porteous, J. A. Innes, A. P

Safety assessment of inhaled xylitol in subjects with cystic fibrosis

Presentation transcript:

Blood basophils from cystic fibrosis patients with allergic bronchopulmonary aspergillosis are primed and hyper-responsive to stimulation by aspergillus allergens Yael Gernez, Colleen E. Dunn, Cassie Everson, Erin Mitsunaga, Lakshmi Gudiputi, Karolina Krasinska, Zoe A. Davies, Leonore A. Herzenberg, Rabindra Tirouvanziam, Richard B. Moss Journal of Cystic Fibrosis Volume 11, Issue 6, Pages 502-510 (December 2012) DOI: 10.1016/j.jcf.2012.04.008 Copyright © 2012 European Cystic Fibrosis Society. Terms and Conditions

Fig. 1 Surface CD203c, CD63 and CD123 levels in blood basophils at baseline in CF-ABPA, CF-AC and CF patients. Shown are box plots (delimited by 25th and 75th percentiles, with median line and whiskers respresenting 10th and 90th percentiles) for CD203c, CD63 and CD123 levels in blood basophils from CF (N=12, light grey) patients, CF-AC (N=12, dark grey), CF-ABPA (N=11, black). Differences between groups were evaluated with the Wilcoxon rank-sum test. Non-significant differences are omitted. Journal of Cystic Fibrosis 2012 11, 502-510DOI: (10.1016/j.jcf.2012.04.008) Copyright © 2012 European Cystic Fibrosis Society. Terms and Conditions

Fig. 2 Surface CD203c levels in blood basophils upon ex vivo stimulation with Af (offending) or peanut (non-offending) allergen extracts. Shown are box plots for CD203c levels in blood basophils from CF (N=12, light grey), CF-AC (N=14, dark grey) and, CF-ABPA (N=11, black) patients upon 10-minute (top) and 30 minute (bottom) allergen stimulation. Differences between groups were evaluated with the Wilcoxon rank-sum test. Differences between Af and peanut stimulations within each group were evaluated with the Wilcoxon signed-rank test. Non-significant differences are omitted. Journal of Cystic Fibrosis 2012 11, 502-510DOI: (10.1016/j.jcf.2012.04.008) Copyright © 2012 European Cystic Fibrosis Society. Terms and Conditions

Fig. 3 Plasma TARC (CCL17) and supernatant histamine measurements in samples from patients with CF, CF-AC and CF-ABPA. (A) Shown are box plots for baseline TARC levels in plasma from CF (N=11, light grey), CF-AC (N=13, dark grey), and CF-ABPA (N=11, black) patients. There were no significant differences in within- and between-group analyses. (B) Shown are mean and standard deviation for histamine levels in blood aliquots from CF (N=8, light grey), CF-AC (N=8, dark grey), and CF-ABPA (N=9, black) patients upon 10-minute (top panels) and 30 minute (bottom panels) allergen stimulation. There were no significant differences in within- and between-group analyses. Journal of Cystic Fibrosis 2012 11, 502-510DOI: (10.1016/j.jcf.2012.04.008) Copyright © 2012 European Cystic Fibrosis Society. Terms and Conditions

Fig. 4 Activation of blood basophils from patients with CF-ABPA following ex vivo stimulation with rAsp f1. (A) Shown are box plots for surface CD203c levels in blood basophil following ex vivo stimulation for 30 minutes with rAsp f1 in CF (N=9, light grey), CF-AC (N=10, dark grey) and, CF-ABPA patients (N=8, black). (B) Titration of the antigen rAsp f1 at 10-minute (top panel) and 30-minute (bottom panel) of stimulation. Shown are histograms for CD203c surface expression in a representative subject with CF-ABPA. Journal of Cystic Fibrosis 2012 11, 502-510DOI: (10.1016/j.jcf.2012.04.008) Copyright © 2012 European Cystic Fibrosis Society. Terms and Conditions